Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in Montana: The Complete Guide for Women, Families, and Survivors
For women across Montana, from the regional medical hubs of Billings and Missoula to the most remote ranching communities in the Hi-Line, the journey through breast reconstruction or aesthetic surgery is one often defined by courage and the hope for restoration. Whether you are a breast cancer survivor recovering at Billings Clinic or a patient navigating a complex revision at Providence St. Patrick Hospital, you were entitled to believe that the medical devices implanted in your body were proven safe for their specific use. Unfortunately, many patients throughout Montana are now discovering that the surgical meshes, acellular dermal matrices (ADM), and bioabsorbable scaffolds used in their “internal bra” or reconstruction procedures were never actually approved by the FDA for use in breast tissue.
We understand the confusion and betrayal felt by women who chose surgery to save their lives or regain their confidence, only to be met with skin-flap necrosis, chronic infection, or a diagnosis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). At The Manginello Law Firm, PLLC, operating under the brand Attorney911, we have spent twenty-seven years fighting for the rights of the catastrophically injured. Led by Ralph Manginello, we are admitted to the United States District Court and possess the technical command of federal regulations required to take on massive device manufacturers like Becton Dickinson, Allergan, and Johnson & Johnson. Our firm is currently litigating high-profile institutional liability cases, such as Bermudez v. Pi Kappa Phi, where we are seeking $10,000,000 for systemic failures. We bring that same aggressive, data-driven methodology to representing women in Montana who have been harmed by defective breast mesh and scaffolds.
If you are experiencing hardness, persistent redness, or fluid collection years after your surgery in Great Falls, Bozeman, or Helena, you are not alone. This guide is built to provide you with the medical, regulatory, and legal answers your surgeon may not have shared. When you are ready to discuss your specific situation, our team, including associate attorney Lupe Peña—who conducts full consultations in fluent Spanish—is available at 1-888-ATTY-911 for a confidential, no-obligation case evaluation.
Understanding the Devices: Mesh, ADM, and Bioabsorbable Scaffolds
Many Montana patients are surprised to learn that their “implant-based reconstruction” actually involved a second, separate device known as a scaffold or mesh. These products are used to create an “internal bra,” providing support for the lower part of the breast or holding a tissue expander in place. To navigate your legal options, it is essential to understand exactly what was placed in your body.
Acellular Dermal Matrix (ADM)
Acellular Dermal Matrix is a biological graft. It is made from human or animal skin (porcine or bovine) that has been “decellularized”—a process intended to remove all cells and DNA while leaving behind a collagen scaffold. The idea is that your own body’s cells will eventually grow into this scaffold. Common brands used in Montana clinics include AlloDerm (Allergan/AbbVie), Strattice, FlexHD (MTF Biologics), and AlloMax (BD/Bard). While common, the FDA has explicitly stated that the safety of these biologic meshes has not been determined for breast surgery.
Bioabsorbable Scaffolds
Unlike permanent synthetic mesh, bioabsorbable scaffolds are designed to dissolve over time. The most controversial of these are made of poly-4-hydroxybutyrate (P4HB). These include the GalaFLEX and Phasix product lines manufactured by Tepha and Becton Dickinson. These devices are marketed to provide a temporary framework that eventually disappears as your natural tissue strengthens. However, we are seeing cases where the scaffold fails to resorb on the 18-to-24-month timeline, leading to palpable mesh edges and chronic inflammation.
Synthetic Surgical Mesh
Sometimes, surgeons use permanent synthetic mesh (like polypropylene) in breast procedures. This is almost always an “off-label” use, meaning the mesh was cleared for hernia or pelvic repair but never for breast tissue. Because breast tissue is highly glandular and sensitive to bacterial colonization, the use of these permanent synthetics can lead to catastrophic infection or “red breast syndrome.”
The Regulatory Failure: The 510(k) Shortcut
A central question for many women in Montana is: How was this allowed to happen? The answer lies in the FDA’s 510(k) clearance pathway. Under 21 USC §360c and 21 CFR Part 807, most medical devices do not undergo the rigorous clinical testing required for “Premarket Approval” (PMA). Instead, they reach the market by claiming they are “substantially equivalent” to a “predicate device” that was already on the market.
In the world of breast scaffolds, this has led to a phenomenon we call “predicate creep.” For example, the manufacturer of GalaFLEX cited a surgical suture as one of its predicate devices to gain clearance. A suture is vastly different from a large mesh sheet meant to support the weight of a breast implant. Because these devices were cleared through 510(k), manufacturers were not required to conduct long-term human clinical trials for breast reconstruction before selling them to surgeons in Missoula, Kalispell, and beyond.
This regulatory shortcut has profound legal implications for your case. Under the landmark Supreme Court ruling in Medtronic v. Lohr, 518 U.S. 470, 510(k) clearance does not preempt state-law negligence or product liability claims. Unlike Class III PMA devices (governed by Riegel v. Medtronic), 510(k) devices like GalaFLEX and Strattice can still be the subject of lawsuits for design defects and failure to warn. We focus on these nuances because a generalist attorney might assume these claims are barred; our experience in the federal courts for the Southern District of Texas and our command of 21 CFR §803 reporting requirements allow us to identify exactly where the manufacturer failed their duty to you.
Verbatim FDA Warnings and Labeling Updates
We believe every Montana patient should see exactly what the Food and Drug Administration has said about these devices. In a critical letter to health care providers dated November 9, 2023, titled “Labeling Updates for BD Mesh Products,” the FDA stated:
“The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA.”
The FDA identified the following affected BD products by name:
- GalaFLEX Lite Scaffold, GalaFLEX Scaffold, GalaFLEX 3D, and 3DR Scaffold.
- Phasix Mesh and Phasix ST Mesh.
Furthermore, in March 2021, the FDA issued a safety communication regarding Acellular Dermal Matrix, specifically naming FlexHD and AlloMax as products with significantly higher rates of explantation, reoperation, and infection. If your surgery at a facility like Benefis Health System in Great Falls used these specific brands, the FDA’s own data supports the fact that you were placed at an elevated risk.
The Spectrum of Complications for Montana Patients
The injuries caused by defective mesh and scaffolds are not just “unfortunate outcomes”—they are often the result of bacterial endotoxins or material failures. We look for the following patterns when evaluating cases for women in Montana:
Red Breast Syndrome and Endotoxin Contamination
Red Breast Syndrome is a noninfectious, sterile inflammation specific to ADM. Peer-reviewed literature, including studies by Nguyen et al., has shown that even after “terminal sterilization,” bacterial endotoxins (lipopolysaccharides) can remain on the matrix. When these toxins interact with your breast tissue, they cause a persistent, bright red rash that mimics an infection but does not respond to antibiotics. The only cure is often the removal of the matrix, which can compromise your entire reconstruction.
Reconstruction Failure and Necrosis
When a scaffold restricts blood flow or triggers an aggressive immune response, the overlying skin can die—a condition called skin-flap necrosis. For a woman who has already endured a mastectomy, the loss of her reconstruction is a secondary trauma. We have seen cases where patients require eight or more revision surgeries, eventually leading to a “flat closure” because the tissue is too damaged to support another implant.
BIA-ALCL: The Textured Implant Cancer
Breast Implant-Associated Anaplastic Large Cell Lymphoma is a CD30-positive, ALK-negative T-cell lymphoma. While the world focused on the July 2019 Allergan BIOCELL recall, many patients do not realize that the textured surface of certain meshes and scaffolds can contribute to the same chronic inflammatory environment that triggers this cancer. With the bellwether trial in the Allergan MDL (MDL 2921) set for October 19, 2026, the procedural clock is ticking for those who have received these textured devices.
BIA-SCC: An Emerging Threat
In September 2022 and March 2023, the FDA updated its warnings to include Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC). This epithelial tumor forms in the capsule around the implant. Unlike ALCL, it has been found with both smooth and textured implants, and it can be much more aggressive. For Montana patients with implants reaching the 10-to-20-year mark, new swelling or lumps must be evaluated immediately with a biopsy of the capsule itself.
The Whistleblower: Dr. Hooman Noorchashm’s Record
We do not just rely on manufacturer-provided data. We examine the public record of whistleblowers who have risked their careers to expose device dangers. Dr. Hooman Noorchashm, a cardiothoracic surgeon and former Medical Director for Becton Dickinson (BD), was terminated in 2022 after raising internal alarms.
Dr. Noorchashm’s allegations are striking: he asserts that breast cancer recurrences in BD’s GalaFLEX clinical trials were withheld from the FDA and that the company participated in off-label marketing that placed thousands of women at risk. He has filed formal citizen petitions with the FDA and sued BD under New Jersey’s Conscientious Employee Protection Act. This investigative authority is a key pillar of our advocacy; we know where the bodies are buried in these corporate histories.
Montana Legal Framework: Your Rights and Deadlines
Navigating a product liability claim in Montana requires a specific understanding of the state’s statutes and court systems.
Statute of Limitations
In Montana, the general statute of limitations for personal injury is three years from the date of the injury (Mont. Code Ann. § 27-2-204). However, the “discovery rule” is critical in device cases. Because many mesh complications accrue over years—BIA-ALCL latency averages 7 to 10 years—the clock may not start until you knew, or reasonably should have known, that the device was the cause of your harm. If you only recently learned about the FDA’s November 2023 warning, your window for filing may still be open, but you must act quickly to preserve your rights.
The Montana Discovery and Expert Standard
Montana is a Daubert state, meaning that expert testimony must meet rigorous scientific standards for reliability. In cases involving bioabsorbable scaffold hydrolysis or ADM endotoxin science, we work with world-class pathologists and toxicologists to ensure your evidence survives the scrutiny of the U.S. District Court for the District of Montana. Whether your case is heard in the Billings, Missoula, or Great Falls division, we bring the same federal-court-admitted experience we utilize in our principal offices in Houston.
Comparative Fault
Montana follows a modified comparative negligence rule. If a jury determines you are partially responsible for your injury, your recovery is reduced by that percentage. However, in medical device litigation, the focus is almost entirely on the manufacturer’s failure to warn your surgeon. Under the “learned intermediary doctrine,” the manufacturer’s primary duty is to inform the doctor. If they hid data—as alleged in the BD whistleblower record—the defense’s ability to blame the surgeon or the patient evaporates.
Why Choose The Manginello Law Firm?
When you are facing a multi-billion-dollar manufacturer, the weight of the opposition can be overwhelming. You need a firm that treats your case with hyper-scientific precision.
- Twenty-Seven Years of Continuous Practice: Ralph Manginello (Bar Card 24007597) has been fighting since 1998. He is a member of the Pro Bono College of the State Bar of Texas, a recognition for those who far exceed service goals.
- Bilingual Advocacy: Lupe Peña understands that language should never be a barrier to justice. We offer full consultations in Spanish, ensuring that Montana’s diverse communities have direct attorney access.
- National Litigation Reach: Our firm is currently lead counsel in Bermudez v. Pi Kappa Phi, a case seeking $10M that has garnered coverage from ABC13, FOX 26, and KHOU 11. We are used to the bright lights of high-stakes litigation.
- No Fee Unless We Recover: We work exclusively on a contingency fee basis. This means we shoulder the entire financial risk of your case. You pay nothing for our investigation, our experts, or our time unless we secure compensation for you.
- Proven Credibility: With an Avvo “Excellent” 8.2 rating and a Martindale-Hubbell Preeminent 5.0 of 5.0 (2015), our ratings are public, verified, and earned through results.
Frequently Asked Questions for Montana Survivors
Is surgical mesh actually approved for breast surgery?
No. As the FDA stated in November 2023, no surgical mesh products have been cleared or approved specifically for breast reconstruction or augmentation. They are used “off-label,” which places a significant burden on the manufacturer and the surgeon to identify and warn of risks.
I had my surgery in Billings five years ago. Is it too late to sue?
Not necessarily. Under Montana’s discovery rule, the three-year limit may not have started until you connected your current complications to the mesh. If you only recently experienced symptoms or learned of the recall, you should contact us immediately at 1-888-ATTY-911 for a time-sensitive review.
Do I have to sue my doctor?
In most cases, the primary target is the manufacturer. Our focus is on the design of the product and the company’s failure to provide accurate safety data. While surgeons are expected to stay informed, our goal is to hold the multibillion-dollar corporations accountable for the products they sell.
What is GalaFLEX and why is it problematic?
GalaFLEX is a P4HB scaffold. While it is marketed as bioabsorbable, we are seeing cases where it does not dissolve properly or where the breakdown products trigger sterile inflammation. The FDA has specifically required BD to update their labels to warn that safety in breast surgery is unproven.
What if my insurance won’t pay for my revision surgery?
We have seen this frequently. Cigna recently declared GalaFLEX “medically necessary” in April 2025, but many other carriers still view these treatments as experimental. Part of our damage model includes all future medical costs and the fight to ensure your insurance covers the specialized care you need.
The Financial Reality: What a Case is Worth
While every case is different, settlements in mesh and device litigation are often substantial. The recent Oct 2024 hernia mesh settlement by BD/Bard involved roughly $1 billion to resolve 38,000 claims. In the breast reconstruction space, where disfigurement and the trauma of cancer are involved, case values can reach into the high six and seven figures depending on the number of revision surgeries and the impact on your quality of life.
We seek damages for:
- Medical Expenses: All past and future surgeries, hospitalizations, and specialized wound care.
- Pain and Suffering: The physical agony of chronic infection and the psychological burden of reconstruction loss.
- Permanent Disfigurement: The long-term impact on your body and self-image.
- Lost Wages: Time away from work for repeatedly failed surgeries.
- Loss of Consortium: The impact on your relationship with your spouse or partner.
Compassionate Next Steps
If you are a woman in Montana wondering why your body is reacting to an implant, or if you have been diagnosed with BIA-ALCL, we are here to provide the technical authority and compassionate support you deserve. We are not a high-volume “settlement mill”—we are a dedicated trial firm with a twenty-seven-year record of taking institutional defendants to court.
Do not allow a manufacturer’s regulatory shortcut to define your health. Call 1-888-ATTY-911 (1-888-288-9911) today for a free, confidential consultation. Whether you are in Missoula, Billings, or the smallest town in Montana, we will listen to your story, examine your medical records, and fight aggressively for the justice you are owed. Hablamos español. No fee unless we win.
Contact The Manginello Law Firm, PLLC / Attorney911:
1-888-ATTY-911
Principal Office: 1177 West Loop South, Suite 1600, Houston, TX 77027
Serving Montana Patients through Federal Court Admission and Strategic Partnership.
Past results do not guarantee future outcomes. The information provided here is for educational purposes and does not substitute for legal advice from a licensed attorney.
